Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia
A legfontosabb adatok
- Ki végzi
- First People's Hospital of Shenyang
- Hol
- Shenyang (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 206 fő, tervezett
- Kezdés
- 2025. júl. 7.
- Várható befejezés
- 2027. júl. 7.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Daphnetin Capsule
- Placebo
- A regiszteradat frissítve
- 2026. augusztus 21.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults aged 50 to 80 with vascular cognitive impairment without dementia. This means memory or thinking problems linked to blood vessel disease. Participants take Daphnetin Capsule or a placebo (dummy capsule) daily for six months.
- Életkor
- 50 to 80 years (both ends included)
- Nem
- All sexes
- A betegség stádiuma
- Memory or other thinking problems for at least 3 months. Thinking is neither normal nor at the level of dementia by DSM-V criteria. MoCA score <26 and ≥18. CDR score ≥0.5 in at least one area and overall CDR score ≤1.
- Korábbi kezelés
- No other interventional clinical study within the last 3 months or now.
A részvétel fő kizáró okai
- Dementia diagnosed before, or acute stroke within 6 months
- Hereditary or inflammatory small vessel disease, or serious mental illness or depression (Hamilton Depression Scale score ≥ 17)
- Severe heart, lung, kidney (creatinine > 2.0 mg/dl or 177 μ mol/L) or liver problems, cancer, or severe hypertension (SBP ≥160mmHg and/or DBP ≥110mmHg)
- Pregnant or breastfeeding women
- No stable, reliable caregiver to help with the study
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Be 50-80 years of age (both ends included)
- Have a complaint of cognitive impairment involving memory and/or other cognitive domains that has persisted for at least 3 months
- Have a cognitive level that is neither normal nor demented according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Criteria ( DSM-V criteria), a Montreal Cognitive Assessment (MoCA scale) score <26 and ≥18, and a Clinical Dementia Rating (CDR) scale score of ≥0.5 in at least one domain and an overall CDR score ≤1
- Have a cognitive level that is neither normal nor demented according to DSM-V criteria, a MoCA scale score <26 and ≥18, and a CDR scale score of ≥0.5 in at least one domain and an overall CDR score ≤1
- Voluntarily participate in this study and sign an informed consent form
Ki nem vehet részt
- Previously diagnosed dementia; vascular cognitive impairment not associated with a condition other than dementia that may affect cognition
- Previously diagnosed hereditary or inflammatory small vessel disease
- Alcoholism, drug addiction, or ongoing use of medications that affect cognitive assessment, such as tranquilizers, sleeping pills, puberty pills, and cholinergics
- Previous allergy or intolerance to the ingredients of Reserpine
- Acute stroke event within 6 months
- Presence of congenital mental retardation and severe neurological or psychiatric disorders
- Illiteracy or severe visual or hearing impairment, severe aphasia, and other factors that may preclude cooperation with neuropsychological evaluation
- Associated depression (Hamilton Depression Scale score ≥ 17), or other unrelated serious mental illness (schizophrenia, bipolar disorder, or delirium)
- Malignant tumors that have been clearly diagnosed, vital organ failure
- Those with bleeding tendency after surgery
- Severe hypertension (Systolic Blood Pressure(SBP)≥160mmHg and/or Diastolic Blood Pressure(DBP)≥110mmHg) is prohibited
- Combined severe cardiac, pulmonary, and renal insufficiency (creatinine > 2.0 mg/dl or 177 μ mol/L), and severe hepatic impairment (aminotransferases more than 3 times normal)
- Pregnant and lactating women are prohibited
- The subject does not have a stable and reliable caregiver or the caregiver is unable to assist the subject in participating in the study
- Patients who have participated in other interventional clinical studies within the last 3 months or are currently participating in other interventional clinical studies
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 50 és 80 év között vagy?
Helyszínek itt: Kína
- Shenyang First People's HospitalShenyang, KínaContact: Li Li, MD PhDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this clinical trial is to understand and evaluate the clinical efficacy and safety of Daphnetin Capsule in patients with vascular cognitive impairment. Changes in the Vascular Dementia Assessment Scale-cog(VADAS-cog) at 6 months were evaluated. Although Daphnetin has a dual neurovascular protective effect, however, there is still a lack of relevant high-quality studies on its role in patients with vascular cognitive impairment, especially in patients with vascular cognitive impairment in non-dementia (VCI-ND), whether it has a role in improving cognitive status needs to be urgently explored in high-quality clinical studies. Researchers are comparing Daphnetin to placebo (a drug-free analog) to see if Daphnetin is effective in treating vascular cognitive impairment. Participants will take either Daphnetin or placebo daily for six months, with follow-up visits every three months and completion of a case report form.
A vizsgálat 2 csoportja
- DaphnetinA vizsgált kezelés
oral Daphnetin Capsule three capsules/tid for up to six months.
Kezelés: Daphnetin Capsule
- PlaceboPlacebo, összehasonlításként
oral Placebo (Daphnetin Capsule simulants) three capsules/tid for up to six months.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia - A Randomized, Double-blind, Placebo-controlled Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06507488: ki vehet részt
- A regiszteradat frissítve
- 2026. augusztus 21.